Dolutegravir + Lamivudine as Initial Dual Therapy
PADDLE
Dolutegravir plus Lamivudine as Initial Dual Therapy
PADDLE: Design

**Study Design: PADDLE**

- **Background**: Pilot, phase 4, single-arm, open-label trial conducted in Argentina to evaluate the efficacy and tolerance of once daily dolutegravir plus lamivudine as initial dual therapy

- **Inclusion Criteria (n = 20)**
  - Age ≥18 years
  - Antiretroviral therapy naive
  - Nadir CD4 count >200 cells/mm³
  - HIV RNA >5,000 and ≤100,000 copies/mL
  - Wild-type baseline genotype
  - No HBV co-infection

- **Regimen (Once daily)**
  - Dolutegravir 50 mg + Lamivudine 300 mg

*Cohort 1*

*Dolutegravir + Lamivudine (n = 10)*

*Cohort 2*

*Dolutegravir + Lamivudine (n = 10)*

4 patients enrolled with HIV RNA >100,000 copies/mL

Cohort 2 patients enrolled following confirmation that 8/10 patients had >1 log decrease in HIV RNA at week 8

## Demographic and Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Dolutegravir + Lamivudine (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median</td>
<td>34 years</td>
</tr>
<tr>
<td>Male</td>
<td>19 (95%)</td>
</tr>
<tr>
<td>Mode of Transmission</td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>15 (75%)</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>HIV RNA (copies/mL), median</td>
<td>24,128</td>
</tr>
<tr>
<td>CD4 count (cells/mm$^3$), median</td>
<td>507</td>
</tr>
</tbody>
</table>

Dolutegravir plus Lamivudine as Initial Dual Therapy

PADDLE: Results

Week 48 Virologic Response (by FDA Snapshot Analysis)

*Other 2 participants:
- 1 committed suicide during study
- 1 developed virologic failure with HIV RNA = 99 copies/mL at week 36 and 246 copies/mL at week 39; patient had HIV RNA <50 copies/mL at week 48 (baseline HIV RNA = 106,320 copies/mL)

**Conclusion**: “This novel dual regimen of dolutegravir and lamivudine warrants further clinical research and consideration as a potential therapeutic option for ARV-therapy-naive patients.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*